HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure.

Abstract
Coenzyme Q10 (CoQ10) treatment, orally administered as 100 mg daily dose, was initiated in a series of patients with advanced heart failure in an open, controlled design. They were all showing an insufficient response to classical therapy with diuretics and digitalis. Twelve patients with various causes of heart failure, classified clinically by echocardiography (ECHO), (12/12), and heart catheterization with endomyocardial biopsy, (10/12), were followed prospectively for a mean period of seven months. Serial assessments: Clinical examination (with questionnaire), ECG, chest X-ray, ECHO, systolic time intervals (STI) and blood levels of CoQ10 were performed. With a mean latency period of 30 days, eight out of 12 patients (67%) showed definite clinical improvement. Subjectively, the patients felt less tired, their general activity tolerance increased and dyspnoea at rest disappeared. There were obvious signs of decreased right-sided stasis (hepatic congestion). The heart rate fell significantly, and the heart volume (chest X-ray) decreased in the eight responders (although n.s.). A significant reduction in the left atrial size (ECHO) was registered, suggesting a reduced preload of the left ventricle, Furthermore, a significant decline in the PEP/LVET ratio (STI) was indicative of an improved myocardial performance. Preliminary CoQ10 withdrawal results showed severe clinical relapse with subsequent improvement on CoQ10 reinstatement, supporting the interpretation that treatment of these patients corrected a myocardial deficiency of CoQ10 and increased contractility. Hence CoQ10 appears to be an effective therapeutic agent in advanced cases of heart failure. This is an attractive circumvention of the traditional principles of therapy: supporting the myocardium directly by ameliorating a supposed underlying mitochondrial dysfunction (exhausted bioenergetics).
AuthorsS A Mortensen, S Vadhanavikit, U Baandrup, K Folkers
JournalDrugs under experimental and clinical research (Drugs Exp Clin Res) Vol. 11 Issue 8 Pg. 581-93 ( 1985) ISSN: 0378-6501 [Print] Switzerland
PMID3836876 (Publication Type: Journal Article)
Chemical References
  • Coenzymes
  • Ubiquinone
  • coenzyme Q10
Topics
  • Adolescent
  • Adult
  • Aged
  • Cardiac Volume (drug effects)
  • Coenzymes
  • Drug Administration Schedule
  • Echocardiography
  • Female
  • Heart Failure (drug therapy)
  • Heart Rate (drug effects)
  • Hemodynamics (drug effects)
  • Humans
  • Male
  • Middle Aged
  • Myocardium (metabolism)
  • Prospective Studies
  • Recurrence
  • Systole (drug effects)
  • Ubiquinone (analogs & derivatives, metabolism, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: